CZChunyan Zhao

Chunyan Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chunyan Zhao has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estrogen Receptor β: An Overview and Update

    by Chunyan Zhao, Karin Dahlman-Wright, Jan-Åke Gustafsson

    The discovery of a second estrogen receptor (ER), designated ERβ (NR3A2), has redefined our knowledge about the mechanisms underlying cellular signaling by estrogens and has broad implications for our understanding of regulation of estrogen-responsive tissues. Highly variable and even contrasting effects of estrogens in different tissues seem to be at least partially explained by different estrogen signaling pathways, involving ERα (NR3A1) and/or ERβ. To date, two key conclusions can be drawn from the significant body of work carried out on the specific roles of the two receptor subtypes in diverse estrogen target tissues. First, ERα and ERβ have different biological functions, as indicated by their specific expression patterns and the distinct phenotypes observed in ERα and ERβ knockout (αERKO and βERKO) mice. Second, ERα and ERβ appear to have overlapping but also unique sets of downstream target genes, as judged from a set of microarray experiments. Thus, ERα and ERβ have different transcriptional activities in certain ligand, cell-type, and promoter contexts, which may help to explain some of the major differences in their tissue-specific biological actions. The phenotypes observed for βERKO mice have suggested certain therapeutic areas to be further explored. The development of ERβ-selective ligands active in animal disease models indicates new avenues for clinical exploration. ERβ agonists are being explored and validated as drugs for a growing number of indications. Hopefully, some ERβ targeted drugs will prove to be efficient in enhancing human health.


  • Estrogen Receptor β2 Negatively Regulates the Transactivation of Estrogen Receptor α in Human Breast Cancer Cells

    by Chunyan Zhao, Jason Matthews, Michel Tujague, Jinghong Wan, Anders Ström, Gudrun Toresson, Eric W-F. Lam, Guojun Cheng, Jan-ÅkE Gustafsson, Karin Dahlman-Wright

    Estrogens, by binding to and activating two estrogen receptors (ERα and ERβ), are critically involved in the development of the mammary gland and breast cancer. An isoform of ERβ, ERβ2 (also called ERβcx), with an altered COOH-terminal region, is coexpressed with ERα in many human breast cancers. In this study, we generated a stable cell line from MCF7 breast cancer cells expressing an inducible version of ERβ2, along with endogenous ERα, and examined the effects of ERβ2 on the ERα protein levels and function. We showed that ERβ2 inhibited ERα-mediated transactivation via estrogen response element and activator protein-1 sites of reporter constructs as well as the endogenous genes pS2 and MMP-1. Chromatin immunoprecipitation assays revealed that ERβ2 expression caused a significant reduction in the recruitment of ERα to both the pS2 and MMP-1 promoters. Furthermore, ERβ2 expression induced proteasome-dependent degradation of ERα. The inhibitory effects of ERβ2 on ERα activity were further confirmed in HEK293 cells that lack functional endogenous ERs. We also showed that ERβ2 can interact with ERα both in vitro and in mammalian cells, which is compatible with a model where ERβ2/ERα heterodimers are targeted to the proteasome. Finally, in human breast cancer samples, we observed that expression of ERβ2 significantly correlated with ERα-negative phenotype. Our data suggest that ERβ2 could influence ERα-mediated effects relevant for breast cancer development, including hormone responsiveness. [Cancer Res 2007;67(8):3955–62]


  • Functional characterization of a novel variant of estrogen receptor beta identified in screening of DNA derived from African Americans

    by Chunyan Zhao, Jan-Åke Gustafsson, Karin Dahlman-Wright

    Information on single nucleotide polymorphisms in the estrogen receptor beta (ERbeta) gene is lacking for the African American population. In this study, we systematically screened the coding and flanking intron regions of the ERbeta gene in 49 healthy African American individuals. We detected four novel variants, of which one variant (963T-->C) resulted in amino acid change from phenylalanine to leucine at position 289, referred to as ERbetaF289L. This receptor variant was characterized in vitro for transcriptional activity and ligand-binding. These studies revealed that ERbetaF289L had reduced estrogen binding affinity and impaired response to 17beta-estradiol induced transactivation compared to the wild-type ERbeta. This novel variant might confer genetic susceptibility to certain endocrine related diseases in African Americans.


  • Mouse Estrogen Receptor β Isoforms Exhibit Differences in Ligand Selectivity and Coactivator Recruitment

    by Chunyan Zhao, Gudrun Toresson, Li Xu, Konrad F. Koehler, Jan-Åke Gustafsson, Karin Dahlman-Wright

    Estrogens exert their physiological effects through two estrogen receptor (ER) subtypes, ERalpha and ERbeta. In mouse, the cloning of an alternative splice variant of the wild-type ERbeta (mERbeta1), mERbeta2, which contains an 18 amino acid insertion in the ligand binding domain, contributed an additional level of complexity to estrogen signaling. In this study we have assayed the interaction of several known ligands with mERbeta1 and mERbeta2. The binding affinity of estradiol was 14-fold higher for mERbeta1 than for mERbeta2. In contrast, raloxifene was dramatically (8-fold) mERbeta2 selective. The selectivity for mERbeta2 was abolished when the 2-arylbenzothiophene core of the raloxifene molecule was tested for binding affinity, demonstrating that the 3-aroyl side chain of raloxifene plays an important role in contributing to its mERbeta2 selectivity. The opposite isoform selectivity found for estradiol and raloxifene in our ligand binding assay was also reflected in the transactivation assay system. That is, mERbeta2 required 10-fold greater estradiol concentrations for maximal activation compared to mERbeta1, whereas raloxifene was more potent in antagonizing estradiol-induced gene expression via mERbeta2 than mERbeta1. The raloxifene core behaved as a pure agonist. Furthermore, mERbeta2 showed significantly decreased estradiol-induced maximal transcriptional activity as compared to mERbeta1. A pull-down assay indicated that the interactions of TIF2 and RAP250 with mERbeta2 were weaker than with mERbeta1. To assess TIF2 and RAP250 interactions with ERs more quantitatively, we examined the interaction of LXXLL containing peptides derived from TIF2 and RAP250 with mERbeta1 and mERbeta2 using surface plasmon resonance analysis. Our results indicate that mERbeta2 interacts with both coactivators with lower affinity, which may explain its reduced transcriptional activity. Taken together, these results suggest that ligand selectivity and coactivator recruitment of the ERbeta isoforms constitute additional levels of specificity that influence the transcriptional response in estrogen target cells.


  • Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation

    by Chunyan Zhao, Eric W-F Lam, Andrew Sunters, Eva Enmark, Manuela Tamburo De Bella, R Charles Coombes, Jan-Åke Gustafsson, Karin Dahlman-Wright

    Two novel estrogen receptor (ER) mRNA isoforms that diverge in their 5'-untranslated regions, ER mRNA (0K-1) and ER mRNA (0N-1), have recently been identified. This indicates that transcription of the human ER gene occurs from at least two different promoters, named promoter 0K and promoter 0N. The aim of this study was to investigate the expression of ER isoforms in primary cultures of normal breast epithelial cells, a panel of breast cancer cell lines and in normal breast and breast cancer tissues; and to examine whether methylation of the two ER promoters is involved in regulation of ER gene expression. Using quantitative real-time PCR techniques, we found that ER mRNA levels were significantly lower in breast cancer cell lines than in primary cultures of normal breast epithelial cells. Bisulfite genomic sequencing analysis revealed that two promoters of the ER gene exhibit distinct methylation patterns. Promoter 0N was unmethylated in normal breast epithelial cells, but extensively methylated in breast cancer cell lines. In contrast, promoter 0K was unmethylated in both normal and malignant breast epithelial cells. We demonstrated a significant correlation between promoter 0N hypermethylation and loss of ER mRNA expression in breast cancer cell lines. Treatment of breast cancer cells with demethylating agent effectively reactivated the expression of ER mRNA. The observations from the cell lines were also reflected in primary breast cancer tumors. Thus, expression of ER mRNA in breast tumors was found to be inversely associated with the degree of methylation of promoter 0N. Our results suggest that a decreased level of ER mRNA may be associated with breast tumorigenesis, and that DNA methylation is an important mechanism for ER gene silencing in breast cancer.


  • Open Access

    The in vivo levels of DNA alkylation products in human lymphocytes are not age dependent: an assay of 7-methyl- and 7-(2-hydroxyethyl)-guanine DNA adducts

    by Chunyan Zhao, Kari Hemminki

    Endogenous DNA damage is assumed to be a major contributor to aging and cancer. This study compares the steady-state levels of 7-methyl- and 7-(2-hydroxyethyl)-guanine DNA adducts in lymphocytes isolated from the younger (mean age 39.8 years) and the older (mean age 82.8 years) healthy subjects. Using a 32P-post-labelling method, these adducts were measured in lymphocyte DNA from a total of 34 subjects. The results show that the amount of both 7-methyl- and 7-(2-hydroxyethyl)-guanine adducts in the younger age group was similar to that in the older age group. Our findings show that at steady-state the levels of DNA alkylation products are independent of age, suggesting that endogenous DNA damage, through methylation or lipid peroxidation, and the repair of such damage may not be deficient in lymphocytes of older individuals.


  • In situ repair of cyclobutane pyrimidine dimers in skin and melanocytic nevi of cutaneous melanoma patients

    by Chunyan Zhao, Erna Snellman, Christer T. Jansen, Kari Hemminki

    The development of cutaneous malignant melanoma (CMM) and its precursor lesions, melanocytic nevi, has been linked to sun exposure. Cyclobutane pyrimidine dimers (CPDs) are the majority of DNA lesions induced by sun exposure. In our study, we investigated if CMM patients have impaired ability to repair CPDs in skin as well as in melanocytic nevi. The repair kinetics were followed up to 3 weeks after exposure to 40 mJ/cm2 of solar simulating radiation. Altogether 12 CMM patients and 10 healthy controls were included in our study. Buttock skin biopsies were taken at 0 hr, 48 hr and 3 weeks after UV exposure, whereas melanocytic nevi and surrounding skin biopsies were taken only at 0 hr and 3 weeks. The CPD levels were measured by a 32P‐postlabeling method. The results showed that the repair rate of CPDs in neither the skin nor the nevi was significantly different between the CMM patients and the control group. For both groups, the repair rate of TT = C was faster than that for TT = T. The important finding is that about 10% of the initial TT = T damage remained unrepaired after 3 weeks, and was detectable in normal epidermis as well as in nevi of all subjects. We also found that the amount of TT = C and TT = T at 0 hr in nevi was significantly lower than that in surrounding skin (Wilcoxon rank sum test, p < 0.05).


  • DNA adducts of 1,3‐butadiene in humans: Relationships to exposure, GST genotypes, single‐strand breaks, and cytogenetic end points

    by Chunyan Zhao, Pavel Vodicka, Radim J. Sram, Kari Hemminki

    The modulation of 1,3‐butadiene (BD)‐induced DNA adducts by occupational exposure, glutathione S‐transferase (GST) genotypes, single‐strand breaks, and cytogenetic end points was studied in 15 workers and 11 controls. The exposed group consisted of 8 smokers and 7 nonsmokers, whereas the control group consisted of 7 nonsmokers and 4 smokers. Among all subjects, the adduct levels in workers lacking GSTM1 were significantly higher than in those who were GSTM1 positive (P = 0.026), and individuals with combined GSTM1(−) and GSTT1(+) genotype had elevated level of adducts compared to that of persons with GSTM1(+) and GSTT1(+) (P = 0.049). The increase in BD–DNA adduct levels in all subjects was significantly related to BD exposure and GSTM1 genotype (linear multiple regression analysis, P = 0.001; P = 0.035). The results suggest that DNA adducts serve as a sensitive and specific biomarker, integrating exposure and host metabolic capacity, although the data are limited to a small number of subjects. Environ. Mol. Mutagen. 37:226–230, 2001.


  • Human DNA adducts of 1,3-butadiene, an important environmental carcinogen

    by C. Zhao, Radim Sram

    The N-1-(2,3,4-trihydroxybutyl)adenine (N-1-THB-Ade) adducts induced by 1,3-butadiene (BD) were analysed from lymphocytes of 15 workers occupationally exposed to BD and 11 controls by (32)P-post-labelling using HPLC with radioactivity detection. The difference in the adduct levels between the BD-exposed workers (4.5 +/- 7.7 adducts/10(9) nucleotides) and the controls (0.8 +/- 1.2 adducts/10(9) nucleotides) was statistically significant (Wilcoxon rank sum test, P = 0.038). This study shows for the first time BD-induced DNA adducts in humans and suggests that N-1-THB-Ade adducts may be used to biomonitor human exposure to BD.